BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

524 related articles for article (PubMed ID: 18854347)

  • 1. Osteopontin might be involved in bone remodelling rather than in inflammation in ankylosing spondylitis.
    Choi ST; Kim JH; Kang EJ; Lee SW; Park MC; Park YB; Lee SK
    Rheumatology (Oxford); 2008 Dec; 47(12):1775-9. PubMed ID: 18854347
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Changes of clinical response and bone biochemical markers in patients with ankylosing spondylitis taking etanercept.
    Woo JH; Lee HJ; Sung IH; Kim TH
    J Rheumatol; 2007 Aug; 34(8):1753-9. PubMed ID: 17610317
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Effects of infliximab and etanercept, two types of anti-tumor necrosis factor-alpha inhibitor on serum level of matrix metalloproteinase 3 expression in patients with ankylosing spondylitis].
    Yang CH; Huang F; Deng XH; Zhang JL; Zhang LY; Guo JH; Liang DF; Wang LS; Zhang YM
    Zhonghua Yi Xue Za Zhi; 2006 Sep; 86(35):2451-4. PubMed ID: 17156669
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Erythrocyte sedimentation rate, C-reactive protein level, and serum amyloid a protein for patient selection and monitoring of anti-tumor necrosis factor treatment in ankylosing spondylitis.
    de Vries MK; van Eijk IC; van der Horst-Bruinsma IE; Peters MJ; Nurmohamed MT; Dijkmans BA; Hazenberg BP; Wolbink GJ
    Arthritis Rheum; 2009 Nov; 61(11):1484-90. PubMed ID: 19877087
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor alpha blockers in ankylosing spondylitis.
    Rudwaleit M; Listing J; Brandt J; Braun J; Sieper J
    Ann Rheum Dis; 2004 Jun; 63(6):665-70. PubMed ID: 15037444
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationship of serum TWEAK level to cytokine level, disease activity, and response to anti-TNF treatment in patients with rheumatoid arthritis.
    Park MC; Chung SJ; Park YB; Lee SK
    Scand J Rheumatol; 2008; 37(3):173-8. PubMed ID: 18465450
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Etanercept exerts beneficial effects on articular cartilage biomarkers of degradation and turnover in patients with ankylosing spondylitis.
    Maksymowych WP; Poole AR; Hiebert L; Webb A; Ionescu M; Lobanok T; King L; Davis JC
    J Rheumatol; 2005 Oct; 32(10):1911-7. PubMed ID: 16206346
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Clinical study of etanercept for treating ankylosing spondylitis].
    Liang LQ; Zhan ZP; Ye YJ; Fu D; Xu HS; Yang XY
    Nan Fang Yi Ke Da Xue Xue Bao; 2008 Aug; 28(8):1349-51. PubMed ID: 18753057
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum leptin levels correlate with interleukin-6 levels and disease activity in patients with ankylosing spondylitis.
    Park MC; Lee SW; Choi ST; Park YB; Lee SK
    Scand J Rheumatol; 2007; 36(2):101-6. PubMed ID: 17476615
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MRI in predicting a major clinical response to anti-tumour necrosis factor treatment in ankylosing spondylitis.
    Rudwaleit M; Schwarzlose S; Hilgert ES; Listing J; Braun J; Sieper J
    Ann Rheum Dis; 2008 Sep; 67(9):1276-81. PubMed ID: 18006539
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human leukocyte antigen-G in ankylosing spondylitis and the response after tumour necrosis factor-alpha blocker therapy.
    Chen CH; Liao HT; Chen HA; Liu CH; Liang TH; Wang CT; Tsai CY; Chou CT
    Rheumatology (Oxford); 2010 Feb; 49(2):264-70. PubMed ID: 20008091
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characteristics and treatment responses of patients satisfying the BSR guidelines for anti-TNF in ankylosing spondylitis.
    Gadsby K; Deighton C
    Rheumatology (Oxford); 2007 Mar; 46(3):439-41. PubMed ID: 17255137
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum osteopontin as a predictive marker of responsiveness to methotrexate in juvenile idiopathic arthritis.
    Masi L; Ricci L; Zulian F; Del Monte F; Simonini G; Capannini S; De Martino M; Brandi ML; Falcini F
    J Rheumatol; 2009 Oct; 36(10):2308-13. PubMed ID: 19684155
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trend towards increased arterial stiffness or intima-media thickness in ankylosing spondylitis patients without clinically evident cardiovascular disease.
    Mathieu S; Joly H; Baron G; Tournadre A; Dubost JJ; Ristori JM; Lusson JR; Soubrier M
    Rheumatology (Oxford); 2008 Aug; 47(8):1203-7. PubMed ID: 18524805
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Messenger ribonucleic acid expression profile in peripheral blood cells from RA patients following treatment with an anti-TNF-alpha monoclonal antibody, infliximab.
    Sekiguchi N; Kawauchi S; Furuya T; Inaba N; Matsuda K; Ando S; Ogasawara M; Aburatani H; Kameda H; Amano K; Abe T; Ito S; Takeuchi T
    Rheumatology (Oxford); 2008 Jun; 47(6):780-8. PubMed ID: 18388148
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of osteopontin in chronic rhinosinusitis with and without nasal polyps.
    Lu X; Zhang XH; Wang H; Long XB; You XJ; Gao QX; Cui YH; Liu Z
    Allergy; 2009 Jan; 64(1):104-11. PubMed ID: 19076536
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inflammatory biomarkers, disease activity and spinal disease measures in patients with ankylosing spondylitis after treatment with infliximab.
    Visvanathan S; Wagner C; Marini JC; Baker D; Gathany T; Han J; van der Heijde D; Braun J
    Ann Rheum Dis; 2008 Apr; 67(4):511-7. PubMed ID: 17644552
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Ankylosing Spondylitis Disease Activity Score is a highly discriminatory measure of disease activity and efficacy following tumour necrosis factor-α inhibitor therapies in ankylosing spondylitis and undifferentiated spondyloarthropathies in China.
    Xu M; Lin Z; Deng X; Li L; Wei Y; Liao Z; Li Q; Wei Q; Hu Z; Zhang Y; Lin Q; Huang J; Li T; Pan Y; Wu Y; Jin O; Yu B; Gu J
    Rheumatology (Oxford); 2011 Aug; 50(8):1466-72. PubMed ID: 21441550
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ASDAS, BASDAI and different treatment responses and their relation to biomarkers of inflammation, cartilage and bone turnover in patients with axial spondyloarthritis treated with TNFα inhibitors.
    Pedersen SJ; Sørensen IJ; Garnero P; Johansen JS; Madsen OR; Tvede N; Hansen MS; Thamsborg G; Andersen LS; Majgaard O; Loft AG; Erlendsson J; Asmussen K; Jurik AG; Møller J; Hasselquist M; Mikkelsen D; Skjødt T; Lambert R; Hansen A; Østergaard M
    Ann Rheum Dis; 2011 Aug; 70(8):1375-81. PubMed ID: 21551511
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlation between plasma TNF-alpha, IGF-1, biochemical markers of bone metabolism, markers of inflammation/disease activity, and clinical manifestations in ankylosing spondylitis.
    Lange U; Teichmann J; Stracke H
    Eur J Med Res; 2000 Dec; 5(12):507-11. PubMed ID: 11147993
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.